RxDoctor Payments Data

Katherine Clark

Primary Care · Whitsett, NCNPI 1043678170

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Abbott at 39.3% of the total.

$2,011in general payments, 2019–2025

Across 58 payments — averaging $34.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$790
  • Novo Nordisk$413
  • AstraZeneca$344
  • Lilly USA, LLC$148
  • Amgen$63
  • Phathom Pharmaceuticals, Inc.$33
  • plus $221 from 10 others

What the payments were for

  • Food & beverage$1,96198%
  • Other$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,011 in reported general payments places this provider in the 75th percentile of 236 primary care providers in North Carolina.

See all primary care providers in North Carolina

Medicare billing

Part B allowed, 2024
$63,468
Medicare patients
166
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$80,804
OzempicSemaglutide39$62,432
JardianceEmpagliflozin27$39,777
EliquisApixaban30$39,205
JanuviaSitagliptin Phosphate19$27,529
TrulicityDulaglutide14$20,426
Soliqua 100-33Insulin Glargine/Lixisenatide19$17,742
Breo ElliptaFluticasone/Vilanterol27$13,516
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$11,576
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$9,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,764
SymbicortBudesonide/Formoterol Fumarate13$7,305
XareltoRivaroxaban12$6,143
Atorvastatin Calcium347$4,651
Gabapentin170$3,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$148$101,23056 claims
Novo NordiskOzempic$413$62,43239 claims
PfizerEliquis$26$39,20530 claims
AstraZenecaSymbicort$344$7,30513 claims
AbbVieSynthroid$31$1,33616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 236 primary care providers in North Carolina.

Other primary care in Whitsett

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →